<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00565656</url>
  </required_header>
  <id_info>
    <org_study_id>06-PP-05</org_study_id>
    <secondary_id>AFSSAPS number:060748</secondary_id>
    <nct_id>NCT00565656</nct_id>
  </id_info>
  <brief_title>A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts</brief_title>
  <official_title>A Phase II Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to IPSS) With Excess of Marrow Blasts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this phase II trial are to test the efficacy and tolerance of Bevacizumab&#xD;
      in MDS patients with excess of marrow blasts and to evaluate the impact of Bevacizumab on&#xD;
      angiogenesis and erythropoiesis.&#xD;
&#xD;
      To limit the myelotoxicity observed in the preliminary phase II study, Bevacizumab will be&#xD;
      administrated at the initial dose of 5 mg/kg.&#xD;
&#xD;
      The primary endpoint will be response: Complete Remission (CR), Partial Remission (PR) and&#xD;
      hematological improvement (HI) according to IWG criteria (see appendix 3).&#xD;
&#xD;
      The secondary endpoints will be survival, response duration, side effects, evaluation of&#xD;
      angiogenesis (bone marrow microvessel density, VEGF plasma level, VEGF mRNA expression,&#xD;
      HIF-1alpha expression).&#xD;
&#xD;
      The design of this study consists of three study periods: pre-treatment (screening),&#xD;
      treatment (loading and maintenance), and follow-up. All patients will participate in the&#xD;
      study for at least 12 weeks of therapy, a 4-week follow-up visit, and long-term follow-up&#xD;
      unless the criteria for planned or unplanned early discontinuation are met.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone marrow evaluation Peripheral blood evaluation Cytogenetic response Hematologic improvement (HI)</measure>
    <time_frame>Before the first injection, weekly during twenty weeks and four weeks after the last injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoints will be survival, side effects</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEVACIZUMAB</intervention_name>
    <description>Administration of Bevacizumab</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MDS patient with excess of marrow blasts (≥ 5%) including RAEB, RAEB-t and CMML with&#xD;
             leucocytes &lt; 10 000/mm3 according to FAB classification&#xD;
&#xD;
          -  IPSS int-1, int-2 or high&#xD;
&#xD;
          -  Age &gt; 60 years (younger adults may be included, but only in the absence of donor for&#xD;
             allogeneic stem cell transplantation, and if contra-indication to intensive&#xD;
             chemotherapy)&#xD;
&#xD;
          -  No previous allogeneic SCT or intensive anthracycline-Ara C chemotherapy.&#xD;
&#xD;
          -  Adequate renal function:&#xD;
&#xD;
               -  Serum creatinine ≤ 1.25 x ULN or calculated creatinine clearance ≥ 50 mL/min AND&#xD;
&#xD;
               -  Urine dipstick for proteinuria &lt; 2+. Patients discovered to have ≥ 2+ proteinuria&#xD;
                  on dipstick urinalysis at baseline should undergo a 24 hour urine collection and&#xD;
                  must demonstrate ≤ 1 g of protein in 24 hours&#xD;
&#xD;
          -  Adequate liver function:&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 x upper limit of normal (ULN) AND Asparagine&#xD;
                  aminotransferase (AST), alanine aminotransferase (ALT) &lt; 2.5 x ULN in patients&#xD;
                  without liver metastases&#xD;
&#xD;
          -  International normalised ratio (INR) ≤1.5 and prothrombin time (PPT) ≤ 1.5 x ULN&#xD;
             within 7 days prior to enrolment&#xD;
&#xD;
          -  If female, should not be pregnant or breast-feeding. Women with an intact uterus&#xD;
             (unless amenorrhoeic for the last 24 months) must have a negative serum pregnancy test&#xD;
             within 28 days prior to enrollment into the study. If a serum pregnancy test is not&#xD;
             performed within 7 days prior to the first dose of bevacizumab, a confirmatory urine&#xD;
             test (within 7 days prior to the first dose of bevacizumab) is required.&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  Patient with health insurance&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Therapy related MDS (after chemo or radiotherapy) for a previous neoplasm or other&#xD;
             disease including AML&#xD;
&#xD;
          -  A preexisting thrombocytopenia &lt; 20 000/mm3&#xD;
&#xD;
          -  Major surgery (including open biopsy), significant traumatic injury within 28 days&#xD;
             prior to enrolment or anticipation of the need for major surgery during study&#xD;
             treatment&#xD;
&#xD;
          -  Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to&#xD;
             the first bevacizumab infusion&#xD;
&#xD;
          -  Prior tumor (except localized cervix carcinoma or cutaneous basal cell carcinoma)&#xD;
             unless in remission for at least 3 years.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Current or recent (within 10 days of first dose of bevacizumab) use of aspirin (&gt; 325&#xD;
             mg/day)&#xD;
&#xD;
          -  Uncontrolled hypertension (blood pressures: systolic &gt; 150 mmHg and/or diastolic &gt; 100&#xD;
             mmHg)&#xD;
&#xD;
          -  Clinically significant (i.e., active) cardiovascular disease for example CVA (≤6&#xD;
             months before enrollment), myocardial infarction (≤ 6 months before enrollment),&#xD;
             unstable angina, congestive heart failure NYHA Class ≥ II, serious cardiac arrhythmia&#xD;
             requiring medication during the study and might interfere with regularity of the study&#xD;
             treatment, or not controlled by medication&#xD;
&#xD;
          -  Non-healing wound, active peptic ulcer or bone fracture&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess&#xD;
             within 6 months of enrolment&#xD;
&#xD;
          -  Women with an intact uterus (unless amenorrhoeic for the last 24 months) not using&#xD;
             effective, non-hormonal means of contraception (intrauterine contraceptive device,&#xD;
             barrier method of contraception in conjunction with spermicidal jelly or surgically&#xD;
             sterile) during the study and for a period of 6 months following the last&#xD;
             administration of bevacizumab. Men who do not agree to use effective contraception&#xD;
             during the study and for a period of 60 days following the last administration of&#xD;
             bevacizumab&#xD;
&#xD;
          -  Investigational treatment for MDS within 6 weeks of treatment onset&#xD;
&#xD;
          -  Patients unable to give informed consent or to be followed up adequately&#xD;
&#xD;
          -  Known hypersensitivity to a product from Chinese Hamster Ovary mammalian cell or to a&#xD;
             recombinant humanized monoclonal antibody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence LEGROS, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of clinical hematology</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paoli-Calmette Institut</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Clinical hematology, Archet Hospital, CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Onco-Hematology, Caremeau Hospital, CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of clinical hematology, Robert Debré Hospital</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology and Oncology, CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of clinical hematology</name>
      <address>
        <city>Vandoeuvre</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>November 28, 2007</study_first_submitted>
  <study_first_submitted_qc>November 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2007</study_first_posted>
  <last_update_submitted>December 7, 2011</last_update_submitted>
  <last_update_submitted_qc>December 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic syndromes (int-1, int-2 and high risk according to IPSS) with excess of marrow blasts including CMML with leucocytes&lt;10 000/mm3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

